ClinicalTrials.gg
Not yet recruitingNCT07940933NISE-1Updated Nov 17, 2026

Niacin and Selenium Combination Therapy in Patients With Septic Shock

A Phase 2 interventional study of Niacin and Placebo for Niacin in Septic Shock, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Seoul National University Hospital · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Shock, Septic with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Shock, Septic · Korea, Republic of.

Planned enrollment
6th of 11
148 · median 148
Started
2026
with 1 other
Phase 2
4 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
2 of 12
Seoul National University Hospital

Among the 12 studies in Shock, Septic with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.

Shock, Septic

1,080 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

3 of the 12 studies in Shock, Septic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Shock, Septic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.

The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.

Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.

The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.

Read the detailed description

Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.

Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.

The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • Septic Shock
  • Niacin
  • Selenium
  • Organ Dysfunction
  • Oxidative Stress
  • Glutathione Redox Cycle
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 years or older, irrespective of sex or race.
  • Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:

Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.

Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.

A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.

Written provided by the participant or an authorized representative.

Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Age younger than 19 years.
  • Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit.
  • Expected death within 72 hours because of the severity of illness.
  • Patients for whom aggressive treatment is not being provided in accordance with an advance directive.
  • Known pre-existing liver failure with a score of 10 or greater.
  • Lack of from the participant or an authorized representative.
  • Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Niacin plus Selenium

    Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

    Drug: Niacin · Drug: Selenium

  • Placebo comparator
    Placebo

    Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

    Drug: Placebo for Niacin · Drug: Placebo for Selenium

Interventions

  • DrugNiacin

    Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

  • DrugPlacebo for Niacin

    Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

  • Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

  • DrugPlacebo for Selenium

    Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

06

What researchers measure

Primary outcomes

  1. Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7

    Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission.

    Time frame: Hospital day 7

Secondary outcomes

  1. 28-Day Survival

    Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method.

    Time frame: From hospital admission (hospital day 0) through day 28

  2. 90-Day Survival

    Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method.

    Time frame: From hospital admission (hospital day 0) through day 90

  3. Length of Intensive Care Unit Stay

    Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90.

    Time frame: From hospital admission (hospital day 0) through hospital day 90

  4. Duration of Mechanical Ventilation

    Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90.

    Time frame: From hospital admission (hospital day 0) through hospital day 90

Other outcomes

  1. Pharmacologic, Antioxidant, and Mechanistic Biomarkers

    Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels.

    Time frame: At enrollment, 72 hours (±6 hours), and day 7

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.

Access criteria: De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

Of 36 non-industry phase 2 interventional studies under Shock, Septic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 17 months is below that.

Counting every sponsor, half of 41 studies reached it within 29 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Nov 16, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940933
Responsible party
Woon Yong Kwon (Professor, Seoul National University Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

WOON YONG KWON, MD, PhD
Contact
kwy711@hanmail.net
82-2-2072-0326
Hayoung Kim, MD, PhD
Contact
mogu13@naver.com
82-2-2072-3257
WOON YONG KWON, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niacin · Selenium

Start the discussion